RT Journal Article
SR Electronic
T1 Early phylodynamics analysis of the COVID-19 epidemics in France
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.03.20119925
DO 10.1101/2020.06.03.20119925
A1 Danesh, Gonché
A1 Elie, Baptiste
A1 Michalakis, Yannis
A1 Sofonea, Mircea T
A1 Bal, Antonin
A1 Behillil, Sylvie
A1 Destras, Grégory
A1 Boutolleau, David
A1 Burrel, Sonia
A1 Marcelin, Anne-Geneviève
A1 Plantier, Jean-Christophe
A1 Thibault, Vincent
A1 Simon-Loriere, Etienne
A1 van der Werf, Sylvie
A1 Lina, Bruno
A1 Josset, Laurence
A1 Enouf, Vincent
A1 Alizon, Samuel
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/06/04/2020.06.03.20119925.abstract
AB France was one of the first countries to be reached by the COVID-19 pandemics. Here, we analyse 196 SARS-Cov-2 genomes collected between Jan 24 and Mar 24 2020, and perform a phylodynamics analysis. In particular, we analyse the doubling time, reproduction number (ℛt) and infection duration associated with the epidemic wave that was detected in incidence data starting from Feb 27. We show that a slowing down of the epidemic spread can be detected in Mar, which is consistent with the implementation of the national lock-down on Mar 17. The inferred distributions for the infection duration and ℛt are in line with those estimated from contact tracing data. Overall, this analysis shows the potential to use sequence genomic data to inform public health decisions in an epidemic crisis context.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGonche Danesh is supported by a doctoral grant from the Fondation pour la Recherche Medicale (FRM grant number ECO20170637560). No other external funding was available for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We follow the GISAID agreement.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequences data originated from the Global Initiative on Sharing All Influenza Data (GISAID, https://www.gisaid.org/) and are listed in Appendix Table S1. https://platform.gisaid.org/